New figures released by GlobalData have shed light on the top locations for mergers and acquisitions in the pharmaceuticals industry.
The data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in the most recent quarter (2022 Q1). That’s down from 20 deals announced in the previous quarter (2021 Q4).
India also performed well over the most recent quarter, with 11 deals (up from six in 2021 Q4).
Which countries are emerging as M&A powerhouses?
As well as being a top location for M&A dealmaking in the pharmaceuticals industry, India has also seen the largest uptick in recent months. The country has seen 15 deals announced over the last two complete quarters, up from an average of just eight deals every six months between 2019 and 2021.
That's the largest increase in M&A dealmaking in the pharmaceuticals industry for any country.
Despite being a top location for M&A dealmaking in the pharmaceuticals industry, the US has had a difficult few months, with just 28 deals announced in the last two complete quarters.
That's a decrease compared the country's average of 58 deals announced every six months between 2019 and 2021, and the sharpest decrease in M&A dealmaking in the pharmaceuticals industry experienced by any country in recent months.
Globally, the situation is looking distinctly positive for mergers and acquisitions in the pharmaceuticals industry.
A total of 125 deals were announced in the last quarter, up from 99 deals in the previous quarter and from an average of 76 deals per quarter over the previous three years.
GlobalData's deals database
GlobalData tracks the performance and activities of more than 675,000 companies in over 200 countries around the world.
The data analytics firm's deals database includes the details of approximately one million deals, ranging from mergers and acquisition to venture capital financing, equity offerings and debt offerings.